58 results
8-K
EX-99.1
le5o1fbx
8 Jun 22
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
a14qi1ch
30 Dec 21
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
7:05am
8-K
EX-99.2
wj3 i6qa8lsvkml
17 Nov 21
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
8:36am
8-K
EX-99.1
c5ljssxcxkqd3r0
9 Aug 21
Company Ended the Quarter With Cash of Approximately $379 Million
6:56am
PRE 14A
5k47ekm4 96d
2 Aug 21
Preliminary proxy
4:31pm